Glenmark Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Equivalents	-	11,763	16,757	16,583	11,592	14,105
Short-Term Investments	-	-	63.45	57.81	90.67	57.33
Cash & Short-Term Investments	11,763	11,763	16,821	16,641	11,683	14,163
Cash Growth	-31.02%	-30.07%	1.08%	42.44%	-17.51%	23.43%
Accounts Receivable	-	49,634	33,419	18,584	36,652	31,011
Other Receivables	-	-	5,710	8,225	5,743	5,576
Receivables	-	49,634	39,130	26,809	42,394	36,588
Inventory	-	34,308	30,285	25,131	23,736	24,998
Prepaid Expenses	-	-	1,053	266.9	2,275	2,199
Other Current Assets	-	17,293	5,667	5,434	27,167	4,876
Total Current Assets	-	112,997	92,955	74,281	107,255	82,823
Property, Plant & Equipment	-	43,174	38,614	35,375	41,951	46,117
Long-Term Investments	-	423.56	605	7,958	472.77	556.64
Goodwill	-	828.64	702.66	673.59	736.19	600.19
Other Intangible Assets	-	24,234	13,900	12,672	23,427	22,254
Long-Term Deferred Tax Assets	-	12,466	11,241	10,497	18,059	16,861
Other Long-Term Assets	-	4,955	2,478	2,130	1,816	1,620
Total Assets	-	199,079	160,496	143,586	193,717	170,833
Accounts Payable	-	37,439	25,795	25,359	20,004	22,887
Accrued Expenses	-	-	11,132	12,473	14,427	7,168
Short-Term Debt	-	-	16,815	8,334	3,500	3,700
Current Portion of Long-Term Debt	-	-	-	1,572	1,456	7,286
Current Portion of Leases	-	1,072	922.62	886.43	830.39	916.78
Current Income Taxes Payable	-	945.29	283.74	2,910	984.98	931.2
Other Current Liabilities	-	24,308	4,722	6,652	9,848	4,005
Total Current Liabilities	-	63,764	59,670	58,186	51,051	46,894
Long-Term Debt	-	-	5,127	-	38,521	25,717
Long-Term Leases	-	4,863	1,862	1,517	1,771	2,000
Long-Term Deferred Tax Liabilities	-	12.31	585.88	2.8	5.14	314.95
Other Long-Term Liabilities	-	25,321	4,760	5,405	3,976	1,525
Total Liabilities	-	93,961	72,005	65,111	95,324	76,452
Common Stock	-	282.2	282.19	282.19	282.17	282.17
Additional Paid-In Capital	-	-	16,866	16,866	16,854	16,854
Retained Earnings	-	-	89,140	80,160	96,026	93,564
Comprehensive Income & Other	-	104,839	-17,793	-18,828	-18,422	-19,834
Total Common Equity	105,121	105,121	88,494	78,479	94,739	90,866
Minority Interest	-	-3.16	-3.71	-3.8	3,653	3,515
Shareholders' Equity	105,118	105,118	88,491	78,475	98,393	94,381
Total Liabilities & Equity	-	199,079	160,496	143,586	193,717	170,833
Total Debt	5,935	5,935	24,727	12,309	46,079	39,620
Net Cash (Debt)	5,827	5,827	-7,906	4,331	-34,396	-25,458
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	20.64	20.64	-28.02	15.35	-121.90	-90.22
Filing Date Shares Outstanding	282.25	282.22	282.19	282.19	282.17	282.17
Total Common Shares Outstanding	282.25	282.22	282.19	282.19	282.17	282.17
Working Capital	-	49,233	33,284	16,095	56,205	35,929
Book Value Per Share	372.48	372.48	313.60	278.11	335.75	322.03
Tangible Book Value	80,059	80,059	73,891	65,134	70,576	68,012
Tangible Book Value Per Share	283.67	283.67	261.85	230.82	250.12	241.04
Land	-	-	471.82	461.25	423.45	688.97
Buildings	-	-	18,588	17,556	16,069	17,211
Machinery	-	-	35,618	32,155	32,052	34,167
Construction In Progress	-	-	5,420	4,193	10,658	9,211